Commentary on “Abiraterone in metastatic prostate cancer without previous chemotherapy.” Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.: N Engl J Med 2013;368(2):138–48 [Epub 2012 Dec 10]; N Engl J Med 2013;368(6):584

Autor: Trump, Donald L.
Zdroj: In Urologic Oncology: Seminars and Original Investigations November 2013 31(8):1846-1846
Databáze: ScienceDirect
Externí odkaz: